News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Investors interested in stocks from the Banks - Foreign sector have probably already heard of Grupo Financiero Galicia (GGAL) and Sumitomo Mitsui (SMFG). But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look. There …
Sharemaestro market context Trend signal active 52 weeks +18.5% · Next-week setup positive 59.9%This article analyzes Grupo Financiero Galicia S.a. (GGAL) using AI models to provide trading strategies and risk management parameters. It identifies weak near-term sentiment but strong long-term potential, highlighting a significant risk/reward setup. The analysis offers specific entry, target, and stop-loss points for position …
Sharemaestro market context Trend signal active 52 weeks +18.5% · Next-week setup positive 59.9%Grupo Financiero Galicia (NASDAQ: GGAL) has announced the payment of its second cash dividend installment for fiscal year 2025, totaling Ps. 13,333,257,333.33. The company previously announced this dividend schedule on June 30, 2026, which was approved during the Ordinary Shareholders' Meeting on April 28, …
Seven analysts have raised Grupo Financiero Galicia S.A.'s average 12-month price target from $70.02 to $71.45, with forecasts ranging from $44 to $103 per share. This new target suggests a potential upside of approximately 45% based on the July 29th closing price. The consensus …
Sharemaestro market context Trend signal active 52 weeks +18.5% · Next-week setup positive 59.9%Grupo Financiero Galicia SA (GGAL) has an institutional shareholding score of 3.00, placing it 250th out of 394 in the Banking Services industry. The institutional shareholding proportion increased by 7.61% quarter-over-quarter to 25.13%. ETHSX is the largest institutional shareholder, holding 0.65% of outstanding shares …
The article reports on Elicio Therapeutics Inc.'s (ELTX) institutional confidence score, which stands at 3.00, placing it 192nd out of 385 in the Biotechnology & Medical Research industry. The institutional shareholding proportion increased by 37.43% quarter-over-quarter, reaching 15.12%. James Simons is noted as the …
This article provides financial information for Elicio Therapeutics, Inc (HAM:9HA), specifically focusing on its price to sales ratio. The content lists the company's trading information on the Hamburg Stock Exchange and indicates that no trades have occurred for the period. It also details the …
This article provides a detailed cash flow statement for Elicio Therapeutics Inc (ELTX), including quarterly and annual data for operating, investing, and financing activities. It presents financial figures such as net income, capital expenditures, and changes in working capital across multiple fiscal years. The …
This article provides working capital per share data for Elicio Therapeutics, Inc (HAM:9HA) on the Hamburg Stock Exchange. The market was closed at the time of publication, with no trades recorded. The content is presented as part of TradingView's financial data offerings.
BofA Securities has reiterated its Buy rating on Grupo Financiero Galicia (GGAL.US). The article does not provide further details regarding the rationale behind this rating or any financial targets.
Grupo Financiero Galicia S.A. (NASDAQ:GGAL) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $68.33, exceeding its $50.00 opening price. Insider buying activity has increased significantly, with Director Silvestre Vila Moret acquiring 224,000 shares for $1.2 million …
The article discusses the revenue breakdown of Elicio Therapeutics Inc (ELTX). It states that relevant data regarding business segments, regional revenue, and profit contribution have not been disclosed by the company yet. The page provides current stock information for ELTX, including its market cap …
This article provides a detailed breakdown of Elicio Therapeutics Inc (ELTX) shareholder structure, listing major shareholders and institutional holdings. It highlights key entities like GKCC, LLC and Knoll Capital Management, LLC, their proportions, and also categorized shareholder types. The report also tracks changes in …
Absolute Gestao de Investimentos Ltda. recently acquired a new position of 168,677 shares, valued at approximately $7.88 million, in Grupo Financiero Galicia S.A. This investment makes Grupo Financiero Galicia the 23rd largest holding in Absolute Gestao de Investimentos Ltda.'s portfolio, representing about 0.9% of …
Elicio Therapeutics Inc (ELTX) is a clinical-stage biotechnology company focused on developing immunotherapies for cancer, specifically targeting mutant KRAS, BRAF, and TP53. Despite a recent weak market performance, the company exhibits strong fundamentals and technicals and is considered fairly valued. Analysts have given it …
Grupo Financiero Galicia (GGALN) has released its Q1 2024 earnings report, significantly beating EPS expectations with an actual EPS of $28.22 against a consensus of $20.68. The company also reported actual revenue of $56.33 billion, marking a 29.08% year-over-year increase. The next earnings report …
The article discusses the revenue breakdown of Elicio Therapeutics Inc (ELTX). It states that relevant data regarding business segments, regional revenue, and profit contribution have not been disclosed by the company yet. The page provides current stock information for ELTX, including its market cap …
Grupo Financiero Galicia SA Class B (BCBA:GGALB) generated 8.45 trillion ARS in revenue last year. The Bank segment was its top performer, contributing 6.14 trillion ARS, and Argentina was the dominant region, accounting for 9.29 trillion ARS. The company's financial overview highlights its primary …
This article provides a comprehensive stock analysis of Grupo Financiero Galicia SA (GGAL) by TradingKey. It highlights the company's healthy fundamentals, high growth potential, and "Buy" ratings from multiple analysts with a target price of $66.000. While its valuation is considered fairly valued within …
Wall Street analysts project a 28.95% upside for Grupo Financiero Galicia (GGAL) based on a mean price target of $64.67. While price targets alone can be misleading, the stock also shows strong agreement among analysts on positive earnings estimate revisions, suggesting potential for an …
Sharemaestro market context Trend signal active 52 weeks +18.5% · Next-week setup positive 59.9%Moerus Capital Management LLC has acquired a new stake in Grupo Financiero Galicia S.A. (NASDAQ:GGAL), purchasing 175,098 shares valued at approximately $8.18 million. This new position represents about 3.0% of Moerus Capital Management's investment portfolio. Insiders have also been actively buying shares, with Director …
Grupo Financiero Galicia SA (GGAL) shares fell 5.8% to $50.15, marking a significant overvaluation according to its GF Value estimate of $26.10, despite a strong growth rank and insider buying. The company's current P/E ratio of 113.7x is drastically higher than its 5-year median, …
Momentum investors typically don't time the market or "buy low and sell high." In other words, they avoid betting on cheap stocks and waiting long for them to recover. Instead, they believe that "buying high and selling higher" is the way to make far …
Sharemaestro market context Trend signal active 52 weeks +18.5% · Next-week setup positive 59.9%This article lists several ETFs that hold Grupo Financiero Galicia SA Sponsored ADR Class B stocks. It provides a table detailing each ETF's market
This article provides a detailed analysis of Grupo Financiero Galicia S.a. (NASDAQ: GGAL), indicating a neutral near and mid-term outlook but a long-term positive bias. It highlights a significant 68.5:1 risk-reward setup targeting a 19.4% gain, and outlines institutional trading strategies including position, momentum …
This Investing.com article reports on a Form 4 filing for Elicio Therapeutics Inc. on July 17. The Form 4 is a U.S. Securities and Exchange Commission document used to report changes in beneficial ownership of a company's stock by insiders. The article indicates that …
Elicio Therapeutics, Inc. (ELTX) has granted its Chief Strategy and Financial Officer, Preetam Shah, 60,833 stock options at an exercise price of $3.20 per share, as detailed in a Form 4 SEC filing. These options expire on July 16, 2036, and will vest in …
Elicio Therapeutics (ELTX) has granted 64,643 stock options to Christopher Haqq, Executive Vice President, Head of R&D, and Chief Medical Officer. The options have an exercise price of $3.20 per share, expire on July 16, 2036, and vest in two 50% tranches on July …
Elicio Therapeutics, Inc. (ELTX) has granted 52,832 stock options to its Chief Scientific Officer, Peter DeMuth. The options have an exercise price of $3.20 per share and will expire on July 16, 2036. The shares will vest in two equal installments, 50% on July …
Search by ticker symbol or company name and select a result to open its chart.